Aging is a whole-body issue, but the FDA has been set up to address specific diseases. The longevity coalition agrees that this is an important problem and suggests that the FDA “be charged with developing new guidelines for testing interventions that do not necessarily target a single specific disease but that retard, arrest, or reverse the structural degeneration and loss of functionality associated with aging.”
